Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCOWAN, Andrew J.
dc.contributor.authorALLEN, Christine
dc.contributor.authorBARAC, Aleksandra
dc.contributor.authorBASALEEM, Huda
dc.contributor.authorBENSENOR, Isabela
dc.contributor.authorCURADO, Maria Paula
dc.contributor.authorFOREMAN, Kyle
dc.contributor.authorGUPTA, Rahul
dc.contributor.authorHARVEY, James
dc.contributor.authorHOSGOOD, H. Dean
dc.contributor.authorJAKOVLJEVIC, Mihajlo
dc.contributor.authorKHADER, Yousef
dc.contributor.authorLINN, Shai
dc.contributor.authorLAD, Deepesh
dc.contributor.authorMANTOVANI, Lorenzo
dc.contributor.authorVuong Minh Nong
dc.contributor.authorMOKDAD, Ali
dc.contributor.authorNAGHAVI, Mohsen
dc.contributor.authorPOSTMA, Maarten
dc.contributor.authorROSHANDEL, Gholamreza
dc.contributor.authorSHACKELFORD, Katya
dc.contributor.authorSISAY, Mekonnen
dc.contributor.authorCuong Tat Nguyen
dc.contributor.authorTung Thanh Tran
dc.contributor.authorBach Tran Xuan
dc.contributor.authorUKWAJA, Kingsley Nnanna
dc.contributor.authorVOLLSET, Stein Emil
dc.contributor.authorWEIDERPASS, Elisabete
dc.contributor.authorLIBBY, Edward N.
dc.contributor.authorFITZMAURICE, Christina
dc.date.accessioned2019-01-17T13:28:22Z
dc.date.available2019-01-17T13:28:22Z
dc.date.issued2018
dc.description.abstractINTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates. We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region. We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95% uncertainty interval [UI], 121 000-155 480) incident cases of MM with an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95% UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106% to 192% for all SDI quintiles. The 3 world regions with the highest ASIR of MM were Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95% UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence of MM is highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipJanssen
dc.description.sponsorshipAbbvie
dc.identifier.citationJAMA ONCOLOGY, v.4, n.9, p.1221-1227, 2018
dc.identifier.doi10.1001/jamaoncol.2018.2128
dc.identifier.eissn2374-2445
dc.identifier.issn2374-2437
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29827
dc.language.isoeng
dc.publisherAMER MEDICAL ASSOCeng
dc.relation.ispartofJama Oncology
dc.rightsopenAccesseng
dc.rights.holderCopyright AMER MEDICAL ASSOCeng
dc.subject.othertransplantationeng
dc.subject.otherlenalidomideeng
dc.subject.otherguidelineseng
dc.subject.otherriskeng
dc.subject.wosOncologyeng
dc.titleGlobal Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016eng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryNoruega
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countrySérvia
hcfmusp.affiliation.countryIêmen
hcfmusp.affiliation.countryFrança
hcfmusp.affiliation.countryJordânia
hcfmusp.affiliation.countryIsrael
hcfmusp.affiliation.countryÍndia
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryVietnã
hcfmusp.affiliation.countryHolanda
hcfmusp.affiliation.countryIrã
hcfmusp.affiliation.countryEtiópia
hcfmusp.affiliation.countryNigéria
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisors
hcfmusp.affiliation.countryisoye
hcfmusp.affiliation.countryisofr
hcfmusp.affiliation.countryisojo
hcfmusp.affiliation.countryisoil
hcfmusp.affiliation.countryisoin
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisovn
hcfmusp.affiliation.countryisonl
hcfmusp.affiliation.countryisoir
hcfmusp.affiliation.countryisoet
hcfmusp.affiliation.countryisong
hcfmusp.affiliation.countryisono
hcfmusp.author.externalCOWAN, Andrew J.:Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
hcfmusp.author.externalALLEN, Christine:Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
hcfmusp.author.externalBARAC, Aleksandra:Univ Belgrade, Belgrade, Serbia
hcfmusp.author.externalBASALEEM, Huda:Aden Univ, Aden, Yemen
hcfmusp.author.externalCURADO, Maria Paula:Accamargo Canc Ctr, Sao Paulo, Brazil; Int Prevent Res Inst, Ecully, France
hcfmusp.author.externalFOREMAN, Kyle:Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
hcfmusp.author.externalGUPTA, Rahul:West Virginia Bur Publ Hlth, Charleston, WV USA
hcfmusp.author.externalHARVEY, James:Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
hcfmusp.author.externalHOSGOOD, H. Dean:Albert Einstein Coll Med, Bronx, NY 10467 USA
hcfmusp.author.externalJAKOVLJEVIC, Mihajlo:Univ Kragujevac, Kragujevac, Serbia; Univ Washington, Ctr Hlth Trends & Forecasts, Seattle, WA 98195 USA
hcfmusp.author.externalKHADER, Yousef:Jordan Univ Sci & Technol, Dept Community Med Publ Hlth & Family Med, Irbid, Jordan
hcfmusp.author.externalLINN, Shai:Univ Haifa, Haifa, Israel
hcfmusp.author.externalLAD, Deepesh:Postgrad Inst Med Educ & Res, Candigarh, India
hcfmusp.author.externalMANTOVANI, Lorenzo:Univ Milano Bicocca, Milan, Italy
hcfmusp.author.externalVuong Minh Nong:Duy Tan Univ, Inst Global Hlth Innovat, Danang, Vietnam
hcfmusp.author.externalMOKDAD, Ali:Int Prevent Res Inst, Ecully, France
hcfmusp.author.externalNAGHAVI, Mohsen:Int Prevent Res Inst, Ecully, France
hcfmusp.author.externalPOSTMA, Maarten:Univ Med Ctr Groningen, Groningen, Netherlands
hcfmusp.author.externalROSHANDEL, Gholamreza:Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Iran; Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran
hcfmusp.author.externalSHACKELFORD, Katya:Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
hcfmusp.author.externalSISAY, Mekonnen:Haramaya Univ, Haramaya, Ethiopia
hcfmusp.author.externalCuong Tat Nguyen:Duy Tan Univ, Inst Global Hlth Innovat, Danang, Vietnam
hcfmusp.author.externalTung Thanh Tran:Duy Tan Univ, Inst Global Hlth Innovat, Danang, Vietnam
hcfmusp.author.externalBach Tran Xuan:Haramaya Univ, Haramaya, Ethiopia; Johns Hopkins Univ, Baltimore, MD USA; Hanoi Med Univ, Hanoi, Vietnam
hcfmusp.author.externalUKWAJA, Kingsley Nnanna:Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria
hcfmusp.author.externalVOLLSET, Stein Emil:Int Prevent Res Inst, Ecully, France
hcfmusp.author.externalWEIDERPASS, Elisabete:Karolinska Inst, Dept Med Epidemiol & Biostat, Solna, Sweden; Canc Registry Norway, Inst Populat Based Canc Res, Dept Res, Oslo, Norway
hcfmusp.author.externalLIBBY, Edward N.:Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
hcfmusp.author.externalFITZMAURICE, Christina:Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; Univ Washington, Div Hematol, Seattle, WA 98195 USA
hcfmusp.citation.scopus382
hcfmusp.contributor.author-fmusphcISABELA JUDITH MARTINS BENSEñOR
hcfmusp.description.beginpage1221
hcfmusp.description.endpage1227
hcfmusp.description.issue9
hcfmusp.description.volume4
hcfmusp.origemWOS
hcfmusp.origem.pubmed29800065
hcfmusp.origem.scopus2-s2.0-85053397909
hcfmusp.origem.wosWOS:000444765300015
hcfmusp.publisher.cityCHICAGOeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAttal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750eng
hcfmusp.relation.referenceAustralian Public Assessment Report for Lenalidomide, 2016, AUSTR PUBL ASS REP Leng
hcfmusp.relation.referenceFerlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210eng
hcfmusp.relation.referenceFitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735eng
hcfmusp.relation.referenceFleming KA, 2017, AM J CLIN PATHOL, V147, P15, DOI [10.1093/AJCP/AQW143, 10.1093/ajcp/aqw143]eng
hcfmusp.relation.referenceFonseca R, 2017, LEUKEMIA, V31, P1915, DOI 10.1038/leu.2016.380eng
hcfmusp.relation.referenceForeman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1eng
hcfmusp.relation.referenceGoldstein DA, 2017, ONCOTARGET, V8, P71548, DOI 10.18632/oncotarget.17742eng
hcfmusp.relation.referenceGratwohl A, 2015, LANCET HAEMATOL, V2, pE91, DOI 10.1016/S2352-3026(15)00028-9eng
hcfmusp.relation.referenceHay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-Xeng
hcfmusp.relation.referenceHowlader N, 1975, SEER CANC STAT REVeng
hcfmusp.relation.referenceKonstantinopoulos PA, 2006, J NATL MED ASSOC, V98, P1860eng
hcfmusp.relation.referenceLandgren O, 2006, BLOOD, V107, P904, DOI 10.1182/blood-2005-08-3449eng
hcfmusp.relation.referenceMcCarthy PL, 2017, J CLIN ONCOL, V35, P3279, DOI 10.1200/JCO.2017.72.6679eng
hcfmusp.relation.referenceMcNeil DG Jr, NY TIMESeng
hcfmusp.relation.referenceMiranda-Filho Adalberto, 2018, Lancet Haematol, V5, pe14, DOI 10.1016/S2352-3026(17)30232-6eng
hcfmusp.relation.referenceNaghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9eng
hcfmusp.relation.referenceNaghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2eng
hcfmusp.relation.referenceNeal RD, 2014, BRIT J CANCER, V110, P584, DOI 10.1038/bjc.2013.791eng
hcfmusp.relation.referenceNwabuko OC, 2017, CANCER MANAG RES, V9, P189, DOI 10.2147/CMAR.S126136eng
hcfmusp.relation.referenceOmoti Caroline Edijana, 2007, J Pak Med Assoc, V57, P341eng
hcfmusp.relation.referencePerrotta C, 2012, J OCCUP MED TOXICOL, V7, DOI 10.1186/1745-6673-7-25eng
hcfmusp.relation.referenceRajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402eng
hcfmusp.relation.referenceRaju GK, 2018, CLIN PHARMACOL THER, V103, P67, DOI 10.1002/cpt.871eng
hcfmusp.relation.referenceSEER* Stat Database: Incidence, 1969, SEER STAT DAT INCeng
hcfmusp.relation.referenceSustainable Development Goals, SUST DEV GOALSeng
hcfmusp.relation.referenceTan D, 2013, LANCET ONCOL, V14, pE571, DOI 10.1016/S1470-2045(13)70404-2eng
hcfmusp.relation.referenceVos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2eng
hcfmusp.relation.referenceWei X, 2018, CANC RESeng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication6911f59e-7ec9-4ad2-b746-580bf8b3d64d
relation.isAuthorOfPublication.latestForDiscovery6911f59e-7ec9-4ad2-b746-580bf8b3d64d
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_COWAN_Global_Burden_of_Multiple_Myeloma_ASystematic_Analysis_for_2018.PDF
Tamanho:
16.56 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03